Predicting how many people might receive treatment with new therapies for Alzheimer's disease.
作者信息
Underwood Benjamin R
机构信息
Fulbourn Hospital, Cambridge, UK
出版信息
J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):793. doi: 10.1136/jnnp-2024-333941.
Abstract
摘要
相似文献
1
Predicting how many people might receive treatment with new therapies for Alzheimer's disease.预测可能有多少人会接受针对阿尔茨海默病的新疗法治疗。
J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):793. doi: 10.1136/jnnp-2024-333941.
2
Immunology and immunotherapy of Alzheimer's disease.阿尔茨海默病的免疫学与免疫治疗
Nat Rev Immunol. 2006 May;6(5):404-16. doi: 10.1038/nri1843.
3
Predictor Factors of Perceived Health in Family Caregivers of People Diagnosed with Mild or Moderate Alzheimer's Disease.轻度或中度阿尔茨海默病患者的家庭照顾者感知健康的预测因素。
Int J Environ Res Public Health. 2019 Oct 7;16(19):3762. doi: 10.3390/ijerph16193762.
4
Use of unproven therapies by people with Alzheimer's disease.阿尔茨海默病患者使用未经证实的疗法。
J Am Geriatr Soc. 1995 Jul;43(7):747-50. doi: 10.1111/j.1532-5415.1995.tb07043.x.
5
Obstacles and opportunities in Alzheimer's clinical trial recruitment.阿尔茨海默病临床试验招募中的障碍与机遇
Health Aff (Millwood). 2014 Apr;33(4):574-9. doi: 10.1377/hlthaff.2013.1314.
6
Delusions in Alzheimer's disease: a review.阿尔茨海默病中的妄想：综述
J Neuropsychiatry Clin Neurosci. 1998 Fall;10(4):373-82. doi: 10.1176/jnp.10.4.373.
7
[Anti-ageing therapies in Alzheimer's disease].[阿尔茨海默病的抗衰老疗法]
Rev Esp Geriatr Gerontol. 2018 Jan-Feb;53(1):45-53. doi: 10.1016/j.regg.2017.02.007. Epub 2017 May 24.
8
Perspectives and challenges in patient stratification in Alzheimer's disease.阿尔茨海默病患者分层的观点与挑战。
Alzheimers Res Ther. 2022 Aug 13;14(1):112. doi: 10.1186/s13195-022-01055-y.
9
Impact of new therapies on Alzheimer's disease management. Introduction.
Gerontology. 1999;45 Suppl 1:1-2. doi: 10.1159/000052758.
10
Alzheimer's disease. 1: Pathology, aetiology and treatment.阿尔茨海默病。1：病理学、病因学与治疗
Br J Nurs. 1994;3(20):1060-2. doi: 10.12968/bjon.1994.3.20.1060.
本文引用的文献
1
Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.抗淀粉样蛋白治疗的资格：为阿尔茨海默病的疾病修饰疗法做准备。
J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):796-803. doi: 10.1136/jnnp-2024-333468.
2
Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK.估算英国潜在的阿尔茨海默病疾病修饰疗法的需求。
Br J Psychiatry. 2024 Jun;224(6):198-204. doi: 10.1192/bjp.2023.166.
3
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.多奈单抗用于早期有症状阿尔茨海默病的回复
JAMA. 2023 Dec 19;330(23):2304-2305. doi: 10.1001/jama.2023.21109.
4
Delivering disease modifying treatments in Alzheimer's disease-An old age psychiatry UK perspective.在阿尔茨海默病中提供疾病修饰治疗——英国老年精神病学视角
Int J Geriatr Psychiatry. 2023 Dec;38(12):e6030. doi: 10.1002/gps.6030.
5
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease.评估用于阿尔茨海默病的抗淀粉样蛋白免疫疗法的关键问题。
Brain Commun. 2023 Jun 2;5(3):fcad175. doi: 10.1093/braincomms/fcad175. eCollection 2023.
6
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
Zotero 插件